Navigation Links
Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update
Date:11/3/2009

SOUTH SAN FRANCISCO, Calif., Nov. 3 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today reported financial results for the third quarter ended September 30, 2009, and provided a corporate update.

"During the third quarter, we reached the 320th event target in our pivotal Phase 3 SPEAR trial, which is evaluating picoplatin for the treatment of small cell lung cancer. This event allowed us to collect the data for overall survival analysis," said Jerry McMahon, Ph.D., chairman and chief executive officer of Poniard. "We expect to report top-line results from the SPEAR registration trial this month and plan to present the data at international medical conferences next year. If the top-line results are positive, we plan to initiate a rolling submission of a New Drug Application with the U.S. Food and Drug Administration by year-end, targeting approval and commercial launch of picoplatin in 2010."

Recent Clinical and Corporate Developments

Picoplatin Clinical Update

  • Announced in September that 320 evaluable events (patient deaths) occurred in the pivotal Phase 3 SPEAR (Study of Picoplatin Efficacy After Relapse) trial, evaluating picoplatin in the treatment of small cell lung cancer (SCLC). The 320th event in the registration SPEAR trial was defined in the Special Protocol Assessment with the U.S. Food and Drug Administration (FDA), which allowed the Company to collect the data for overall survival analysis, which is the primary endpoint of the trial. This randomized trial is comparing picoplatin with best supportive care to best supportive care alone without systemic chemotherapy.

Corporate Update

  • Secured a committed equity financing facility in August under which Poniard may, over a
    '/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Poniard Pharmaceuticals to Present at the 2009 UBS Global Life Sciences Conference
2. Poniard Pharmaceuticals Announces Pivotal Phase 3 SPEAR Trial Evaluating Picoplatin in Small Cell Lung Cancer Reaches 320th Event Target
3. Poniard Pharmaceuticals To Present at Three Upcoming Investor Conferences in September
4. Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update
5. Poniard Pharmaceuticals to Host Second Quarter 2009 Financial Results Conference Call on August 4
6. Poniard Pharmaceuticals Appoints Gary A. Lyons to Board of Directors
7. Poniard Pharmaceuticals to Present at the 8th Annual Needham Life Sciences Conference
8. Poniard Pharmaceuticals Files Shelf Registration
9. Poniard Pharmaceuticals to Present at the Leerink Swann Oncology Roundtable Conference
10. Poniard Pharmaceuticals to Present at the 2009 BIO International Convention
11. Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Picoplatin in Patients with Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... , March 4, 2015 Vegalab announced ... in August of last year. As part of the ... Bon Koo continuing his role as CEO for ... of Vegalab S.A., will work alongside Koo and oversee ... - http://photos.prnewswire.com/prnh/20150303/179218 Koo founded ...
(Date:3/3/2015)... - Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a ... target the underlying mechanisms of cancer, today reported financial ... 31, 2014. Effective July 17, 2014, the ... to December 31. As a result of that change, ... quarter and the seven months ended December 31, 2014, ...
(Date:3/3/2015)... Mar. 03, 2015 Research and Markets ... "Gene Therapy Market, 2015 - 2025" report ... Market, 2015-2025" report provides an extensive study on the ... has been carried out in this field for over ... (four available in Asian markets; one approved in the ...
(Date:3/3/2015)... Crown Bioscience, Inc., a leading global drug ... Life Science division specializing in in vivo and in ... first products released include in vivo grade human and ... released in vivo grade monoclonal antibodies against PD-L1 and ... science portfolio with additional antibody products as well as ...
Breaking Biology Technology:Korean Government Program Supports Vegalab's Research and Development 2Korean Government Program Supports Vegalab's Research and Development 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 2Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 7Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 8Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 9Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 10Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 11Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 12Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 2Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 3Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 4Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 5Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 6Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 7Crown Bioscience Launches Life Science Product Catalog 2
... BETHESDA, Md., Oct. 24, 2011 Spherix Incorporated ... in biotechnology for therapy in diabetes, metabolic syndrome ... consulting services to food, supplement, biotechnology and pharmaceutical ... of D-tagatose and SPX-106) reduced dyslipidemia in new ...
... DLVR Therapeutics Inc. ("DLVR") - a privately-held ... based on its proprietary high density lipoprotein-like nanoparticle ... seed round investment bringing the total raised to ... Innovation joins the University Health Network (UHN) and ...
... 24, 2011 Marshall Edwards, Inc. (Nasdaq: MSHL ... novel therapeutics targeting cancer metabolism, announced today that Charles Baltic, ... has been appointed to its board of directors. The appointment ... six and the number of independent directors to five. ...
Cached Biology Technology:Spherix Announces Results from New Preclinical Studies Showing SPX-106T Produces Significant Reductions in Cholesterol, Fat Deposition and Body Weight 2Spherix Announces Results from New Preclinical Studies Showing SPX-106T Produces Significant Reductions in Cholesterol, Fat Deposition and Body Weight 3Spherix Announces Results from New Preclinical Studies Showing SPX-106T Produces Significant Reductions in Cholesterol, Fat Deposition and Body Weight 4DLVR Therapeutics Inc. Raises Additional Capital Adding MaRS Innovation to Investor Base 2DLVR Therapeutics Inc. Raises Additional Capital Adding MaRS Innovation to Investor Base 3Marshall Edwards Appoints Healthcare Investment Banking Veteran Charles Baltic to Board of Directors 2Marshall Edwards Appoints Healthcare Investment Banking Veteran Charles Baltic to Board of Directors 3
(Date:2/5/2015)... 2015  Marken is starting its 35 th ... a new marketing campaign to solidify its place as ... campaign focuses on First as a primary ... The first headline in the series, ... its client,s priorities. Marken recognizes the need to protect ...
(Date:2/5/2015)... Jan. 28, 2015 NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing mobile ... RedChip Global Online CEO Conference on January 29 th ... Gino Pereira , CEO of NXT-ID will present and ... the Wocket smart wallet and its full suite of ...
(Date:1/22/2015)... 2015 Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is pleased ... State of Washington,s Department of Licensing, ... and central issuance system for driver,s licenses and identification cards ... planning and development will start in January 2015, with enrollment ...
Breaking Biology News(10 mins):Marken Launches New Patient-Centric Campaign 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3Valid USA Signs Contract For Washington Driver's License Issuance 2
... use knowledge about methane production by cold-weather microbes on ... similar, carbon-based microbes that could have evolved on Mars, ... three-year project, funded by a $2.4 million grant from ... program, will be led by biogeochemist Lisa Pratt. Her ...
... for informatics professionals, has weighed in on the Federal ... Office of the National Coordinator,s (ONC) call for comments ... set forth by the U.S. Congress and the Administration. ... MD, summarizes AMIA,s comments simply: "Because health IT ...
... 11 May 2011 - Two new research studies published ... in brain development that emerge as vulnerable individuals develop ... with a deletion of a small section of chromosome ... of abnormalities in the structure of the heart and ...
Cached Biology News:NASA project eyes climate change in Greenland -- with a third eye on Mars 2NASA project eyes climate change in Greenland -- with a third eye on Mars 3AMIA identifies areas to strengthen Federal health IT strategic plan 2Brain development goes off track as vulnerable individuals develop schizophrenia 2
... quadrupole 1200L sets the new standard ... - incorporating the latest technologies and ... chromatography analytical needs. The Atmospheric ... Transmission Quadrupole Analyzer provide superior selectivity ...
Human beta IG-H3 MAb (Clone 348506) Keywords: BIGH3, betaIG-H3 Protein Family: Extracellular Matrix Molecules...
Catalase (Control)...
Human RELT/TNFRSF19L Affinity Purified Polyclonal Ab...
Biology Products: